IMR Press / CEOG / Volume 45 / Issue 4 / DOI: 10.12891/ceog3908.2018

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
A disintegrin and metalloproteinase domain-containing protein-12 levels in first-trimester pregnant women
Show Less
1 Department of Clinical Biochemistry, Public Health Laboratory, Adana, Turkey
2 Department of Clinical Biochemistry, Giresun University Medical Faculty, Giresun, Turkey
3 Department of Obstetric and Gynecology, SB Okmeydani Educational and Research Hospital, Istanbul, Turkey
4 Department of Clinical Biochemistry, Yerkoy State Hospital, Yozgat, Turkey
5 Department of Clinical Biochemistry, SB Okmeydani Educational and Research Hospital, Istanbul, Turkey
6 Department of Industrial Engeneering, Istanbul University, Istanbul, Turkey
Clin. Exp. Obstet. Gynecol. 2018, 45(4), 517–522;
Published: 10 August 2018

Aim: In this prospective monocenter study, the authors aimed to investigate the correlations between levels of serum human disintegrin and metalloproteinase domain-containing protein 12 (ADAM12), pregnancy-associated plasma protein A (PAPP-A), serum-free beta hCG (fβ-hCG), and baby birth weights in two groups of pregnant women whose risks for trisomy 21 was found higher and lower than threshold value in first trimester screening test. Materials and Methods: Seventy-nine pregnant women were included the study. Using first trimester screening test, 40 of them were categorized as having above threshold risk (1/250) for trisomy 21 and, 39 of them were below threshold risk. ELISA method was used to measure the levels of serum ADAM12 and chemiluminescence method was used to measure the levels of PAPP-A and fβ-hCG. Results: In pregnant women at risk, ADAM12, PAPP-A multiple of median (MoM), and baby birth weights were found significantly lower than control group (p < 0.001, p < 0.001, and p = 0.029, respectively) while the levels of fβ-hCG MoM were higher than those of control group (p < 0.001). In the group of pregnant women having low birth weight (LBW) babies, ADAM12 levels were found lower than the group having normal birth weight babies (NBW) (p < 0.033). Also, the values of fβ- hCG MoM were found higher in comparison to NBW group (p < 0.029). A positive significant correlation was observed between ADAM12 concentrations and PAPP-A MoM (r = 0.630). Conclusions: Maternal serum ADAM12 levels are useful as biomarkers which support other screening parameters for predicting trisomy 21 risk. Additionally, maternal serum ADAM12 levels could be used for prediction of baby birth weights.
First-trimester screening test
A disintegrin and metalloproteinase domain-containing protein 12
Placenta associated plasma protein-A
Free beta-hCG
Back to top